Mr. Tao Xudong
- Partner, JunHe LLP
Mr. Tao joined JunHe in 2001 and is a senior partner of our capital market practice.
Mr. Tao focuses on initial public offering by Chinese companies in domestic and overseas capital markets and post-listing matters, including: (1) deal structuring; (2) pre-IPO transactions such as M&A, ESOP and PE financing; (3) IPO by Chinese companies in domestic and overseas markets; (4) post-listing securities compliance, employee equity incentive schemes; (5) restructuring, takeover, take-private or re-listing involving listed companies, etc.
In overseas capital market area, Mr. Tao’s most recent deals include: (1) underwriter’s PRC counsel to DPC Dash Ltd. in its HKEX listing in March 2023; (2) underwriter’s PRC counsel to JF Wealth Holdings Ltd. in its HKEX listing in March, 2023; (3) underwriter’s PRC counsel to AIM Vaccine Ltd. in its HKEX listing in 2022; (4) underwriter’s PRC counsel to Microport Medbot Group in its HKEX listing in 2021; (5) underwriter’s PRC counsel to Dingdong (Cayman) Limited in its NYSE listing in 2021; (6) underwriter’s PRC counsel to New Horizon Bio in its HKEX listing in 2020; and (7) issuer’s PRC counsel to Vivo Biotech in its HKEX listing in 2019.
In domestic capital market area, Mr. Tao is the issuer’s counsel to the following in their Scitech Board listing: (1) Baili Pharm, 2023; (2) Transwarp, 2022; (3) Hanova Pharma, 2022; (4) Chengdu HitGen,2020; (5) Zelgen Pharma, 2020, and (6) Shanghai Amologic, 2019. Mr. Tao also acts as the underwriter’s counsel to BeiGene Ltd in its Sci-tech Board listing in 2021 and issuer’s counsel to Ecovacs Robotics in its listing on Main Board of Shanghai Stock Exchange in 2018.
Mr. Tao has been ranked as a “Leading Lawyer” by IFLR and Asia Law since 2012, a Recommended Lawyer by Chambers (Band I, 2020) and a “Stand-out Lawyer” by Thomson Reuters in 2021.